Neovascular Age-Related Macular Degeneration: Optimizing Treatment in the Era of COVID-19 and Beyond

1.00 CME
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

nAMD image for M956 activity


Jointly provided by Postgraduate Institute for Medicine and Catamount Medical Education

Postgraducate Institute of Medicine LogoCatamount Medical Education Logo

Supported by an independent educational grant from Regeneron.


Release Date: April 1, 2021
Expiration Date: April 1, 2022

Estimated Time to Complete Activity:

60 minutes

Target Audience

The target learning audience for this initiative is retina specialists, comprehensive ophthalmologists, and other healthcare professionals involved in the treatment of patients with neovascular AMD.

Learning Objectives

Upon completing this activity, the participant should be better able to:

  • Review current and emerging therapies for neovascular AMD
  • Discuss potential risks and considerations related to COVID-19 that may affect treatment decisions
  • Employ best practices for monitoring disease activity in patients with neovascular AMD during the COVID-19 pandemic
  • Utilize recommendations, along with current evidence, to guide the personalized treatment of neovascular AMD patients

Credit Available

Physicians — maximum of 1.0 AMA PRA Category 1 Credit

All other healthcare professionals completing this course will be issued a statement of participation.


Development Faculty
Dante J. Pieramici, MD
California Retina Consultants

Peter K. Kaiser, MD
Chaney Family Endowed Chair in Ophthalmology Research
Professor of Ophthalmology
Cleveland Clinic Lerner College of Medicine and Cole Eye Institute

Joint Accreditation Statement

Jointly Accredited Provider Logo

In support of improving patient care, this activity has been planned and implemented by Postgraduate Institute for Medicine and Catamount Medical Education. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Dante J. Pieramici, MD
Consulting fees: Adverum, Gemini Therapeutics, Genentech, Regeneron, REGENXBIO
Contracted Research: Adverum, Apellis, Genentech, Regeneron, REGENXBIO, NGM Biopharmaceuticals, Novartis, Stealth BioTherapeutics
Ownership Interest: Gemini Therapeutics

Peter K. Kaiser, MD
Consulting fees: Aerie, Alcon, Allegro, Allergan, Alzheon, Annexon, AsclepiX, Bausch and Lomb, Bayer, Biogen Idec, Bionic Vision Technologies, Biosciences, Boehringer Ingelheim, Carl Zeiss Meditec, Clearside Biomedical, DTx Pharma, Duet Therapeutics, Eyevensys, Galecto, Galimedix, Gemini Therapeutics, Glaukos, Innovent, iRenix, Iveric Bio, jCyte, Kanaph Therapeutics, Kanghong, Kodiak, LensGen, NGM Biopharmaceuticals, Novartis, Ocugenix, Oculis, Ocuphire, OcuTerra Therapeutics, Omeros, Opthea, Oxurion, Palatin, Regeneron, REGENXBIO, Retinal Sciences, Retrotope, Roivant, Samsung Bioepis, Sandoz, Santen, Stealth BioTherapeutics, Sustained Nano Systems, Takeda, Théa

Planners and Managers

PIM planners and managers have nothing to disclose. Catamount Medical Education planners and managers have nothing to disclose.

Instructions for Participation and Credit

There are no fees for participating and receiving CME/CE credit for this activity. During the period of April 1, 2021, through April 1, 2022, participants must read the learning objectives and faculty disclosures and study the educational activity.

If you wish to receive acknowledgement for completing this activity, please complete the evaluation. Upon registering and successfully completing the activity evaluation, your certificate will be made available immediately.



Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.